MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	3/22/2007 2:18:42 AM
	Read Replies (1) of 1826

MGI Pharma "buy," target price raised - update Wednesday, March 21, 2007 4:13:18 AM ET Brean Murray, Carret & Co NEW YORK, March 21 (newratings.com) - Analyst Jonathan Aschoff of Brean Murray maintains his "buy" rating on MGI Pharma Inc (MOGN.NAS). The target price has been raised from $22 to $24. In a research note published yesterday, the analyst mentions that the bronchoscopy and minor surgery trials for the company’s Aquavan drug depicted sufficient efficacy and safety profile of the drug in minimal-to-moderate sedation. MGI Pharma is on-track to filing the NDA for Aquavan in 3Q07 and is expected to receive approval for the drug by 2008, the analyst says.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next